Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer

Table 2

Published reports of SLR in patients with breast cancer.

Authors	Age (y)	Subtype			Treatment regimens	References
		ER	PgR	HER2
Lafon M, et al.	69	0	0	Negative	Nab-paclitaxel plus atezoliumab	[15]
Stoffaës L, et al.	62	95	70	Negative	Palbocicurib plus anastrozole	[16]
Vieira H, et al.	71	90%	95%	Positive	Trasutuzumab plus anastrozole	[17]
Panagiotidis E, et al.	45	Negative	Negative	Positive	Pertuzumab and trastuzumab	[18]
Shin HC, et al.	46	Positive	Positve	Negative	TAM	[19]
. Bhattad PB, et al.	45	Positive	Positive	Negative	TAM	[20]
Martella S, et al.	55	90%	90%	Negative	TAM	[21]
	53	90%	0%	Negative	TAM plus LHRHa	[21]
	53	90%	90%	Negative	TAM plus LHRHa	[21]

ER: estrogen receptors; PgR: progesterone receptors; HER2: human epidermal growth factor type 2; TAM: tamoxifen; LHRHa: luteinizing hormone-releasing hormone agonists.